



**HAL**  
open science

## Spatially hierarchical nano-architecture for real time detection of Interleukin-8 cancer biomarker

Sawsen Azzouzi, Mounir Ben Ali, Francesca Bellagambi, Abdelhamid Elaïssari, Nicole Jaffrezic-Renault, Abdelhamid Errachid, Nadia Zine

► **To cite this version:**

Sawsen Azzouzi, Mounir Ben Ali, Francesca Bellagambi, Abdelhamid Elaïssari, Nicole Jaffrezic-Renault, et al.. Spatially hierarchical nano-architecture for real time detection of Interleukin-8 cancer biomarker. *Talanta*, 2022, 246, pp.123436. 10.1016/j.talanta.2022.123436 . hal-03675524

**HAL Id: hal-03675524**

**<https://hal.science/hal-03675524>**

Submitted on 22 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

# Spatially hierarchical nano-architecture for real time detection of Interleukin-8 cancer biomarker

Sawsen Azzouzi<sup>a</sup>, Mounir Ben Ali<sup>a</sup>, Francesca Bellagambi<sup>b</sup>, Abdelhamid Elaissari<sup>b</sup>, Nicole Jaffrezic-  
Renault<sup>b</sup>, Abdelhamid Errachid<sup>b,\*</sup>, Nadia Zine<sup>b</sup>

<sup>a</sup> University of Sousse, Higher Institute of Applied Sciences and Technology of Sousse, GREENS-ISSAT, Cité  
Ettafala, 4003 IbnKhalidoun Sousse, TUNISIA

<sup>b</sup> University of Lyon 1, Institut des Sciences Analytiques (ISA) – UMR 5280, 69100 Villeurbanne, Lyon,  
FRANCE

\*Corresponding author: Prof. Abdelhamid Errachid

*E-mail address:* [abdelhamid.errachid-el-salhi@univ-lyon1.fr](mailto:abdelhamid.errachid-el-salhi@univ-lyon1.fr)

Telephone: +33 43 74 23 560

Scopus Author ID: 6602163740

## Abstract

In the present work we have developed two hierarchical nano-architectures based electrochemical immunosensors for the detection of interleukin-8 (IL-8) cytokine tumor biomarker. A comparative study has been performed for spatial nano-architectures and their relative sensing to establish the model for real time monitoring. With the first platform, the recognition layer consisted with immobilised IL-8 on aminothiols modified gold electrodes. In the second approach, the activated multi walled carbon nanotubes (MWCNT-COOH) were added in the functionalisation process by covalent attachment between the functionalities NH<sub>2</sub> of aminothiols and the functionalities COOH of carbon nanotubes. The surface topology of the recognition layer has been characterised by atomic force spectroscopy (AFM) and contact angle (CA) measurements. The electrochemical response of the developed sensor was measured by electrochemical impedance spectroscopy (EIS). A side-by-side comparison showed that aminothiols/activated MWCNTs/ anti-IL-8 based impedimetric immunosensor exhibits high reproducibility (The relative standard deviation (R.S.D) = 3.2 %, n = 3) with high stability. The present sensor allows evaluating a lower detection limit of 0.1 pg mL<sup>-1</sup> with a large dynamic sensitivity range from 1 pg mL<sup>-1</sup> to 1000 pg mL<sup>-1</sup> covering the entire clinical therapeutic window. The developed MWCNTs based immunosensor has been calibrated by determining IL-8 in artificial plasma and showed a selective response to IL-8 even in the interfering environment of other cytokines such as Interleukin-1 (IL-1) and Interleukin-6 (IL-6).

**Keywords:** Spatially Hierarchical nano-architecture; Immunosensor; Multi wall carbon nanotubes (MWCNT); Impedance spectroscopy; Interleukin-8; Cancer biomarker.

## 43 **1. Introduction**

44 Early diagnosis of cancer is very important for successful diagnostic of the disease and patient  
45 survival and makes a challenge and critical step for cancer therapy. In fact, it needs accurate  
46 detection of a certain protein biomarkers present trace amount in serum patients of early  
47 stages of cancer disease [1,2,3]. The present traditional assay methods are radio-immunoassay  
48 and enzyme-linked immunosorbent assay (ELISA) [4], immune-polymerase chain reaction  
49 (PCR) assay [5], electrophoretic immunoassay [6], fluorescence immunoassay [4], and mass  
50 spectrometric immunoassay [7]. Most of these existing methods need expensive, sophisticated  
51 instruments and well-controlled experimental conditions. Moreover, ELISA tests are time-  
52 consuming with time-to-results of several hours and are limited in their applicability for  
53 Point-of-Care (PoC) devices. Subsequently, there is a great interest for developing biosensors  
54 for protein detection with a faster and highly sensitive and selective immunological response  
55 [8,9] that leads to reduced costs of treatment with a fundamental understanding of disease  
56 progression. In this context, during the last years, immunosensors were widely used in order  
57 to enhance the biosensors metrological characteristics. These devices combine an antibody as  
58 recognition element with a transducer, which converts optical, electrical, and mass changes of  
59 the solution into a measurable signal following the interaction between the free antigen (Ag)  
60 present in the solution under analysis and the antibody (Ab) anchored to a transducer. Another  
61 advantage of biosensors compared to traditional methods for detecting IL-8 is they can  
62 already be integrated in PoC devices, which are well known to allow faster medical decisions,  
63 to avoid any trouble related to specimen identification and sample transport problems, and the  
64 needing only small sample volumes [9].

65 Interleukin 8 (IL-8) is a bioactive protein produced by many different cells of the immune  
66 system [10]. It is a 8 kDa cytokine that is involved in the inflammatory response with serum  
67 levels in healthy individuals at  $\leq 13 \text{ pg mL}^{-1}$  compared to  $20\text{--}1000 \text{ pg mL}^{-1}$  or more in cancer  
68 patients [11,12]. Increased concentrations of IL-8 have found in the presence of many types of  
69 cancer [13], including squamous cell cancer [11], prostate cell carcinoma [14], thyroid cancers  
70 [12], and pancreatic cancer [15], implying a great clinical interest in the quantification of IL-  
71 8 cytokines for both cancer prognosis and diagnosis [16,17]. Recent research has addressed  
72 the detection and monitoring of IL-8 by biosensing approaches. For instance, Otieno *et al.*  
73 [18] have incorporated an on-line chamber to capture cancer biomarker proteins on magnetic  
74 beads derivatised with 300,000 enzyme labels and 40,000 antibodies into a modular  
75 microfluidic immunoarray. Domnanich *et al* [19] presented a reflective gold chips coated with  
76 polyelectrolyte multilayers for signal enhancement in immunoassays for melanoma-relevant

77 biomarkers. A technique for reversibly encapsulating nanomechanical resonant sensors within  
78 microfluidic channels for the detection of IL-8 in fetal bovine serum was also described by  
79 Waggonera *et al.* [20]. Malhotra *et al.* combined gold nanoparticles surfaces with magnetic  
80 beads massively labelled with horseradish peroxidase enzyme labels to develop an  
81 ultrasensitive electrochemical microfluidic array optimized to measure a four-protein panel of  
82 cancer biomarker proteins [21]. Mandal *et al.* presented an optofluidic biosensor platform for  
83 the concurrent detection of multiple interleukins (IL-4, IL-6, and IL-8), by incorporating a  
84 unique one-dimensional photonic crystal resonator array that enables light-matter interaction  
85 [22]. Hakim *et al.* have fabricated polysilicon nanowire based biosensors using a top-down  
86 process in order to quantify the binding constant of two inflammatory biomarkers: IL-8 and  
87 TNF- $\alpha$  (tumor necrosis factor-alpha) [23]. Hakim *et al.* integrated an enzymatic signal  
88 enhancement scheme onto a multiplexable silicon photonic microring resonator platform for  
89 the detection of IL-8, IL-2 and IL-6 [24]. More recently, other biosensing methods have been  
90 proposed for detecting blood IL-8 at ever-lower levels through the optimization and  
91 continuous progresses of electrochemical detection strategies as well as the use of  
92 nanostructured surfaces. In 2016, Sharma *et al.* [25] proposed a free-label biosensor based on  
93 electrochemical impedance spectroscopy (EIS) that exploited a novel synthetic non-antibody  
94 capture protein based on a cystatin scaffold, managing to reach a sub-pg/mL sensitivity. Low  
95 limits of detection of pg mL<sup>-1</sup> were achieved also by Tonello *et al.* in 2016 [26], by testing  
96 commercially-available carbon sensors modified using two different carbon nanostructures  
97 (e.g. Carbon nanotubes and spherical fullerene) in combination with stripping voltammetry,  
98 and by Verbarq *et al.* in 2017 through the implementation of an optical detection platform  
99 combined with a fluorescent immunoassay [27].

100 It is therefore clear that electrochemical bio-chemical sensors coupled with functionalising  
101 process using nanostructured materials can be considered as a good strategy to improve the  
102 biosensing development. Moreover, further progresses can be achieved by the use of EIS,  
103 which is undoubtedly acknowledged as a powerful tool for interfacial characterization. EIS is  
104 a sensitive technique that monitors the electrical response of the studied system after  
105 application of a periodic small amplitude signal. This technique is a direct method for probing  
106 protein binding events such as those from antibody-antigen interactions [28].

107 Due to their electrical, optical, thermal, and mechanical properties, carbon nanotubes (CNT)  
108 were widely used in the functionalisation of electrodes in order to amplify electrical signals of  
109 the chemical and biological sensors, with an increasing number of applications of CNTs in  
110 several chemical analysis fields [29,30]. The enhancement of CNTs electrode kinetics to

111 different redox species, in terms of increased faradic current and minimisation of the redox  
112 overpotential, has made the nanotubes to be considered as electrocatalytical materials. Thus,  
113 the electronic properties of CNTs and specially their band structure, in terms of density of  
114 electronic states, are of great interest for the interfacial electron transfer between a redox  
115 system in solution and the electrode surface [29–31].

116 This work presents two different functionalisation techniques for the development of an EIS  
117 biosensor for the detection of IL-8. The first functionalisation approach consisted in  
118 immobilising activated IL-8 antibodies on 11-amino-1-undecanethiol modified gold  
119 electrodes in order to create a two-dimensional nano-architecture . The second strategy  
120 provided that , activated multi walled carbon nanotubes (MWCNT-COOH) were added in the  
121 functionalisation process by covalent attachment between the functionalities  $\text{NH}_2$  of  
122 aminothiols and the functionalities COOH of carbon nanotubes. That led to develop a three-  
123 dimensional spatially hierarchical nano-architecture which offers a larger active specific area  
124 in contact with the analyte to enhance the immunosensor performances.

125

## 126 **2. Materials and Methods**

### 127 **2.1 Reagents**

128 Multi-Walled Carbon Nanotubes (MWCNT-COOH) (ref DRP-CNT sol), were provided by  
129 DROPSSENS (Spain). 11-amino-1-undecanethiol was obtained from Sigma Aldrich. N-(3-  
130 dimethylaminopropyl)-N-ethyl-carbodiimide hydrochloride (EDC), N-hydroxysuccinidimide  
131 (NHS) and sodium dodecyl sulfate salt (SDS), used as surfactant was provided by Sigma-  
132 Aldrich (France). Anti-human IL-8 monoclonal antibody (anti IL-8), Recombinant Human IL-  
133 8, Recombinant Human IL-6 and Recombinant Human IL-1 were all purchased from R&D  
134 Systems (France). The bicinchoninic acid protein assay (BCA protein assay) kit was provided  
135 by Pierce (France). The buffer solution used for all experiments was Phosphate Buffer Saline  
136 (PBS; pH=7.4). All solutions were made up in ultrapure water produced by a Millipore Milli-  
137 Q system. Artificial plasma was purchased from Biolabo (France).

138

### 139 **2.2 Instrumentation and experimental details**

140 The different layers grafted onto the gold electrode were characterised by contact angle  
141 measurements using a Dataphysics, Contact Angle System OCA (France). The measurements  
142 were analyzed with a droplet of 4  $\mu\text{L}$  of deionized water, for the untreated gold substrate and  
143 after each stage of the gold substrate treatment. The contact angle has been obtained in three

144 different areas of the given wafer with three separated drops and we have calculated the  
145 statistical validation of the three measurements.  
146 The surface topology of aminothiols/ activated MWCNTs functionalised gold substrates were  
147 investigated using Atomic Force Microscopy (AFM). The AFM measurements were  
148 performed in 'tapping-mode' (TM-AFM) and the respective images were recorded at room  
149 temperature with a Nano- Observer AFM microscope from SCIEN Tec (France).  
150 The UNICO Spectrophotometer Model S-2150 UV-Vis (Spain) was used for the colorimetric  
151 quantification of the amount of anti IL-8 immobilised on the working electrode surface.  
152 Cyclic Voltammetry (CV) and electrochemical impedance spectroscopy (EIS) were  
153 performed in a conventional electrochemical cell containing a three-electrode system using a  
154 VMP3 potentiostat/galvanostat (Bio-logic-Science Instrumentation, France). A reference  
155 electrode (Ag/AgCl) and platinum (Pt) counter electrode wire with a diameter of ~0.5 mm  
156 were used. CV measurements were performed in a mixture of 5 mM K<sub>3</sub>  
157 [Fe(CN)<sub>6</sub>]/K<sub>4</sub>[Fe(CN)<sub>6</sub>] as the redox probe in PBS solution (pH 7.4). The potential was swept  
158 between -200 mV and 600 mV (versus Ag/AgCl) at a rate of 100 mV/s. Impedance  
159 measurements were carried out in the same solution at room temperature. A sinusoidal  
160 excitation signal with amplitude of 10 mV was applied and the impedance spectra were  
161 recorded in the frequency range (0.1 Hz - 100 kHz). The potential polarization was optimized  
162 at - 220 mV. The obtained EIS data were fitted by the EcLab software. All electrochemical  
163 measurements were performed inside a Faraday cage.

164

### 165 **2.3 Antibodies and cytokines preparation**

166 Antibodies and cytokines were diluted in PBS buffer, aliquoted, and stored at -20 °C  
167 following the supplier's protocol. The used cytokines IL-8, IL-1 and IL-6 were aliquoted at  
168 varying concentrations ranging from 1 to 1000 pg mL<sup>-1</sup> and stored at 4 °C.

169

### 170 **2.4 Gold electrodes fabrication**

171 The microelectronics fabrication process for the gold electrodes has been performed at Centro  
172 Nacional de Microelectronica CNM (Barcelona, Spain). The starting material is P-type <100>  
173 silicon 100 mm diameter wafers with a nominal thickness of 525 µm. The process starts with  
174 a dry oxidation process to grow a layer of SiO<sub>2</sub> (780 Å) and afterward a Si<sub>3</sub>N<sub>4</sub> layer of 1000  
175 Å thickness was deposited by low-pressure chemical vapor deposition (LPCVD). For a better  
176 adhesion of Au microelectrodes, a 100 Å of Ti layer was introduced first, and then the 2500 Å

177 of Au layer was sputtered onto the surface. After, the wafer had been diced into individual  
178 chips with size about 1 cm<sup>2</sup>.

179

#### 180 **2.4.1. Gold electrode modification with 11-amino-1-undecanethiol self-assembled** 181 **monolayer**

182 Before functionalisation, the gold electrode was cleaned in an ultrasonic bath for 15 min in  
183 acetone and dried under a N<sub>2</sub> flow. Subsequently, the gold electrode was dipped for 3 min at  
184 room temperature in a piranha solution, and then rinsed with ultrapure water. Subsequently,  
185 working gold electrode was immersed in 1 mM 11-amino-1-undecanethiol (aminothioliol)  
186 solution for 5 h at 4 °C, in order to create an amine layer over the gold support. The substrate  
187 was then rinsed with ethanol to remove the unbonded thiols. It is well known that the  
188 formation of a self-assembled monolayer (SAM) provided functional groups for subsequent  
189 covalent attachment by carbodiimide method to form peptide bonds. In particular, the use of  
190 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), which is currently one of the most  
191 used the hetero-crosslinker for covalent antibody immobilization, provides a stable bond  
192 between a carboxyl group and a primary amine. Hydrophilic residues with chemically reactive  
193 functionalities (e.g. amino, carboxyl, and hydroxyl groups) are generally at the antibody  
194 surface, and the EDC/NHS coupling of antibody amine and carboxyl groups to surface  
195 carboxyl and amine groups represents one of the most used strategies for oriented antibody  
196 immobilization [32]. Moreover, the use of 11-amino-1-undecanethiol proven to provide NH<sub>2</sub>  
197 terminated SAM with a higher antigen/antibody ratio than a COOH terminated SAM [33].

198

### 199 **2.5. Preparation of the immunosensors**

#### 200 **2.5.1. Preparation of aminothioliol / activated anti IL-8 based immunosensor (Platform 1)**

201 The carboxyl groups present in the terminal part of the anti IL-8 antibody (10 µg mL<sup>-1</sup>) were  
202 activated by reaction with 0.2 M NHS and 0.8 M EDC prepared in PBS buffer, for 45 min.


203 The modified anti IL-8 structures were then added to the Au-NH<sub>2</sub> layer for 1h at room  
204 temperature (Fig. 1A). Subsequently, the biosensor was incubated into 1% ethanolamine for  
205 20 min, to deactivate unreacted –COOH groups, which could eventually lead to non-specific  
206 bonds during IL-8 detection stage [9].

#### 207 **2.5.2. Preparation of aminothioliol / activated MWCNTs / anti IL-8 based immunosensor** 208 **(Platform 2)**

209 Before immobilising the carbon nanotubes on aminothioliol functionalised gold electrodes, 17  
210 µL from 0.25 mg/mL MWCNT were dispersed in 183 µL of deionised H<sub>2</sub>O containing 0.1 M

211 sodium dodecyl sulphate (SDS). This produces a final volume of 200  $\mu\text{L}$  of MWCNT-COOH  
212 mixture. Then, 0.2 M solution of NHS and 0.8 M solution of EDC were prepared in PBS in  
213 order to produce a final volume of 200  $\mu\text{L}$ . Afterwards, 200  $\mu\text{L}$  of MWCNT solution and 200  
214  $\mu\text{L}$  of NHS/EDC solution were mixed for 45 min in order to formulate the active EDC/NHS  
215 ester groups on the MWCNTs. Finally, the aminothiols modified working electrode was  
216 incubated in MWCNT/NHS/EDC solution for 2 h at room temperature, and followed this by  
217 rinsing in PBS to remove all non-bound MWCNTs. This produces a  $0.011 \text{ mg mL}^{-1}$   
218 concentration of functionalized MWCNTs [34]. The active NHS ester functionalised carbon  
219 nanotubes MWCNT-COOH attached on gold electrodes were then maintained in contact with  
220  $10 \mu\text{g mL}^{-1}$  of anti IL-8 antibody for 1 h at room temperature (Fig. 2A) to react with the  
221 terminal amino groups of the antibody as already described by []. The excess antibodies were  
222 removed by rinsing with PBS. As done for Platform 1, the IL-8 antibody-modified gold  
223 electrode was treated with 1% ethanolamine solution for 20 min to deactivate unreacted  
224 -COOH groups from MWCNT,. Finally, the substrate was rinsed with PBS.  
225





226

227 **Fig. 1.** Schematic presentation of the main steps for biofunctionalisation process of the developed  
 228 immunosensors: (A) Anti-IL-8 antibody activation and its subsequent immobilization onto the Au-  
 229 NH<sub>2</sub> layer; (B) Immobilization of carbon MWCNT on aminothiols functionalised gold electrodes  
 230 through the activation of MWCNT by using NHS/EDC, followed by anti-IL-8 antibody binding.

231

### 232 2.5.3. Antibody / antigen affinity reaction

233 All procedures were made in triplicate. The antigen solution with increasing concentrations,  
 234 prepared in PBS buffer (pH=7.4) by accurate dilution of a 5 µg/mL stock solution, was  
 235 incubated on the bio-functionalised surface for 30 min at room temperature.

236

## 237 3. Results and discussion


### 238 3.1 Morphological characterisation of the functionalised gold electrode

239 Contact angle (CA) measurements were made to characterise the different functionalisation  
240 steps of the gold electrode. The contact angle was  $81 \pm 2^\circ$  for the bare gold electrode, in  
241 agreement with the expected angle of  $81 \pm 1^\circ$  [36], whilst, the gold electrode treated with  
242 piranha was  $53 \pm 2^\circ$ . This hydrophilic character proves the presence of COOH as the terminal  
243 group. The modification of gold electrode with aminothiols leads to the decrease of the CA to  
244  $26 \pm 2^\circ$ . This signifies that the aminothiols were successfully self-assembled on the gold  
245 electrode. In fact, the thiol function -SH leads to the spontaneous formation of a strong Au-  
246 sulphur interaction that is expected to form a closely packed monolayer [37]. Subsequently,  
247 the immobilisation of the activated MWCNTs leads to a remarkable increase in the contact  
248 angle ( $74 \pm 1^\circ$ ). This reflects the hydrophobic character of carbon nanotubes. Finally, the  
249 decrease of the contact angle to  $62 \pm 2^\circ$  shows the successful immobilisation process of IL-8  
250 antibodies. Images obtained from CA measurements are shown in Fig. 1S (Supplementary  
251 material section).

252 The AFM images of aminothiols functionalised gold electrode after MWCNTs and IL-8  
253 antibodies immobilisation are presented in Fig. 2.

254 Fig. 2A shows round pores corresponding to gold surface. A dispersion of nano-objects is  
255 observed with an average diameter of 30-35 nm and a surface roughness (RMS) of 9.34 nm  
256 which proves the successful immobilisation of carbon nanotubes as MWCNTs bundles. The  
257 length of MWCNT bundles is not observable due to the interaction of the tip with surface  
258 [38,39]. Then, the presence of the IL-8 antibodies on the gold/aminothiols/ MWCNTs based  
259 structure was evident from the significant change observed in the surface roughness with a  
260  $\text{RMS}=3.56$  nm (Fig. 2B). The observed surface was also quite uniform, suggesting that most  
261 of the antibodies had a similar orientation after binding.

262




263  
 264 **Fig. 2.** AFM image of aminothiols modified gold electrode after (A) MWCNTs and (B) IL-8 antibodies  
 265 immobilization.

266

### 267 3.2 Electrochemical characterisation of aminothiols SAMs

268 The compactness and the blocking effect of SAMs modified electrode has been investigated  
 269 using CV through a redox behavior of a reversible  $\text{Fe}(\text{CN})_6^{3-}/\text{Fe}(\text{CN})_6^{4-}$  pair [40–42]. Fig. 3  
 270 illustrates the cyclic voltammograms before and after functionalisation of gold electrodes with  
 271 aminothiols. The oxidation and reduction peaks the bare electrode were recorded at  $\sim 0.301$  V  
 272 and 0.155 V. However, the redox peaks decreased after the formation of SAMs onto the  
 273 working gold electrode. This was attributed to the SAMs acting as an insulating layer that  
 274 blocked the electron transfer at the electrode interface.

275



276


277 **Fig. 3.** Cyclic voltammograms for bare gold and aminothiols modified electrode in 5 mM  $K_3[Fe(CN)_6]/K_4[Fe(CN)_6]$  in PBS (pH=7.4). The scan rate was 100 mV/s.

278

### 279 3.3 Electrical characterisation of the biofilm by impedance spectroscopy

281 EIS was performed to control the building-up of the biofilms based on aminothiols and  
 282 aminothiols / MWCNTs structures at an optimised potential of  $-220$  mV. This value was set  
 283 since it allowed minimizing total impedance of the modified electrode before IL-8 addition  
 284 [43]. Fig. 4 shows the Nyquist diagrams for the assembly of the biofilms on the working gold  
 285 electrode. We notice for the first system, the presence of activated IL-8 antibodies attached to  
 286 the aminothiols layer was confirmed by a decrease of the charge transfer resistance ( $R_{ct}$ ) which  
 287 measures directly the ability of the charge transfer to take place between electrodes and  
 288 surrounding electrolyte.

289



290

291 **Fig. 4.** Nyquist diagram for the impedance measurements (at -0.22 V) vs. Ag/AgCl in PBS solution  
 292 (pH 7.4) corresponding to the various layers grafted onto the gold electrode. Spectra were obtained  
 293 between 0.1 Hz – 100 kHz; amplitude of alternative voltage 10 mV.

294

295 With the MWCNTs based platform, we can observe a significant decrease of the interfacial  
 296 impedance after carbon nanotubes immobilisation that reflects the attachment of the carbon  
 297 nanotubes on aminothiols and brings out their conducting properties. In fact, the MWCNTs  
 298 layer promotes the electron transfer through the layer of thiol and increases the conductivity  
 299 of the system, and therefore the charge transfer rate. Then, the immobilisation of IL-8  
 300 antibodies leads to the decrease of the interfacial impedance. This can be attributed to the  
 301 increase of MWCNTs conductance.

302

### 303 **3.4 Determination of the total concentration of anti IL-8 being modified onto the** 304 **working electrodes**

305 The BCA Protein Assay, which is a biochemical assay commonly used for quantitation of  
 306 total protein in a sample, was used in order to quantify the IL-8 antibodies concentration by  
 307 measuring the net absorbance at 562 nm using a UV-visible spectrophotometer. This assay  
 308 combines the reduction of Cu<sup>2+</sup> to Cu<sup>1+</sup> by protein in an alkaline medium with the highly  
 309 sensitive and selective colorimetric detection of the cuprous cation (Cu<sup>1+</sup>) by bicinchoninic  
 310 acid. First, solutions of anti IL-8 with known concentrations have been prepared and used as  
 311 samples, and analysed by using the BCA protein assay in order to construct the standard  
 312 curve. The tubes containing the standard solutions and the working reagents were covered and

313 incubated at 60°C for 30 min. Then, after cooling all the tubes to room temperature, the  
 314 absorbance (A562 nm) of all the samples was measured within 10 minutes.  
 315 The second step consists in incubating the anti IL-8 modified gold working electrodes with  
 316 unknown immobilised protein concentration using the same protocol and measuring the  
 317 absorbance at 562 nm and finally quantifying the unknown concentration using the standard  
 318 calibration curve. The measured concentrations of anti IL-8 were  $1.3 \pm 0.1 \mu\text{g/mL}$  (R.S.D =  
 319 7.6 %; n = 3) and  $22.1 \pm 1.2 \mu\text{g/mL}$  (R.S.D = 5.4 %; n=3) for aminothiols based immunosensor  
 320 (platform 1) and MWCNTs based three-dimensional nanoarchitecture (platform 2),  
 321 respectively.  
 322 Table 1 summarizes the measured concentrations of anti IL-8 attached to the surface for both  
 323 studied platforms. We can notice that the measured concentration of anti IL-8 was higher in  
 324 the case of MWCNTs based immunosensor ( $22.1 \pm 1.2 \mu\text{g/mL}$ ). This could be due to the  
 325 three-dimensional (3D) structure of MWCNTs based nano-architecture that offers a larger  
 326 specific surface area and subsequently more available recognition sites in contact with the  
 327 analyte.

328


329 **Table 1.** Total concentration of anti IL-8 immobilized onto the electrode.

Structure	Concentration of anti IL-8 immobilized onto the electrode ( $\mu\text{g/mL}$ )	RSD (%; n=3)
Aminothiol / activated anti IL-8	$1.3 \pm 0.1$	7.6
Aminothiol / activated MWCNTs / anti IL-8	$22.1 \pm 1.2$	5.4

330

### 331 **3.5 Impedimetric response of the immunosensors**

332 Before the immobilisation of the antibody, the biosensors were tested by addition of antigen  
 333 (IL-8), no change in the impedance spectrum was observed for both platforms. Then, the anti  
 334 IL-8 functionalised gold electrode was calibrated in presence of increasing concentrations of  
 335 the specific antigen IL-8 ranging from  $1 \text{ pg mL}^{-1}$  to  $1000 \text{ pg mL}^{-1}$ . Antigen–antibody  
 336 interactions were monitored using impedance spectroscopy. The impedance spectra obtained  
 337 after addition of increasing concentrations of antigen (IL-8) are shown as Nyquist plots, in  
 338 Fig. 5A and 5B, where Re Z is the real part and  $-\text{Im Z}$  is the imaginary part of the complex  
 339 impedance Z. A semicircle plot can be observed that is characteristic of a pure resistance in  
 340 parallel with a capacitance [43].



342

343 **Fig. 5.** Examples of Nyquist plots obtained at  $-0.22$  V vs. Ag/AgCl in PBS performing EIS  
 344 measurements on (A) aminothiols / anti IL-8 modified gold electrode (B) aminothiols/ MWCNT/ anti  
 345 IL-8 under various concentrations of IL-8 antigen (pH 7.4, Spectra were obtained between 0.1 Hz –  
 346 100 kHz. Amplitude of Alternative voltage: 10 mV).

347

348 As it can be seen from Fig. 5, at low frequencies, the half-circles diameter decreases clearly  
 349 with the increase of IL-8 concentration for both immunosensors. This can be due to the  
 350 decrease in the electron transfer resistance reflecting the interaction between the IL-8 antigen  
 351 and the bio-functionalised surface. For, the MWCNTs based nano-architecture, the increase of  
 352 MWCNTs conductivity could be explained by the increase of the negative charge of the  
 353 immunocomplexe [39].

354 From an electrochemical point of view, a Randles equivalent circuit can represent the  
 355 solid/electrolyte interface. In such model, the Warburg impedance  $Z_w$  attributed to the mass  
 356 transfer to the electrode surface, is in series with the charge transfer resistance  $R_{ct}$  and both  
 357 are generally in parallel with a double layer capacitance  $C_{dl}$ .  $R_s$  resistance added in series  
 358 represents the resistance of the electrolyte. However, In this work,  $Z_w$  is almost small and  
 359 remains negligible compared with the resistance of the charge transfer  $R_{ct}$  at the  
 360 biofunctionalised gold electrode / electrolyte interface. Subsequently, the impedance spectra  
 361 were fitted with the equivalent circuit, shown as inset in Fig. 4A. It consists of a charge  
 362 transfer resistance  $R_{ct}$  in parallel with a constant phase element CPE. A resistance  $R_s$  was  
 363 added in series with them.

364 The constant phase element CPE reflects the inhomogeneities and defect areas of the layer  
 365 [45]. In fact, it is a capacitance reflecting the non-ideality of the double-layer at the bio-

366 functionalised gold electrode/electrolyte interface due to the roughness and porosity of the  
 367 biofilm and can be expressed as follows:

368

$$369 \quad Z_{\text{CPE}} = \frac{1}{Q(j\omega)^n}$$

370

371 Where Q is a constant, j is the imaginary number,  $\omega$  is the angular frequency and  $0 < n < 1$ .

372 CPE becomes more capacitive, when the value n tends to 1.

373 The different simulated fitting parameters from the impedance data obtained for the

374 increasing IL-8 concentration are summarised in Table 1 and Table 2.

375

376 **Table 2.** Fitting parameters obtained for the aminothiols/activated anti IL-8 based immunosensor.

<b>IL-8 Concentration</b>	<b>Rs (<math>\Omega</math>)</b>	<b>CPE1 (<math>\mu\text{F}</math>)</b>	<b>n</b>	<b>R<sub>ct1</sub> (k<math>\Omega</math>)</b>	<b><math>\chi^2</math> (<math>10^{-3}</math>)</b>
<b>1 pg mL<sup>-1</sup></b>	552 ± 2	1.635 ± 0.005	0.919 ± 0.005	314 ± 1	0.194
<b>150 pg mL<sup>-1</sup></b>	564 ± 1	1.778 ± 0.002	0.919 ± 0.006	309 ± 1	0.192
<b>300 pg mL<sup>-1</sup></b>	587 ± 3	1.726 ± 0.003	0.911 ± 0.008	265 ± 2	0.205
<b>450 pg mL<sup>-1</sup></b>	552 ± 2	1.798 ± 0.001	0.929 ± 0.005	210 ± 3	0.400
<b>600 pg mL<sup>-1</sup></b>	538 ± 2	1.825 ± 0.006	0.939 ± 0.003	150 ± 3	0.527
<b>1000 pg mL<sup>-1</sup></b>	531 ± 3	1.875 ± 0.005	0.938 ± 0.009	116 ± 3	0.542

377

378 **Table 3.** Fitting parameters obtained for the aminothiols/activated MWCNTs/anti IL-8 based  
 379 immunosensor.

<b>IL-8 Concentration</b>	<b>Rs (k<math>\Omega</math>)</b>	<b>CPE2 (<math>\mu\text{F}</math>)</b>	<b>n</b>	<b>R<sub>ct2</sub> (k<math>\Omega</math>)</b>	<b><math>\chi^2</math> (<math>10^{-3}</math>)</b>
<b>1 pg mL<sup>-1</sup></b>	2 ± 0.1	2.798 ± 0.003	0.969 ± 0.001	202 ± 1	0.457
<b>150 pg mL<sup>-1</sup></b>	2 ± 0.1	2.799 ± 0.001	0.969 ± 0.004	167 ± 1	0.393
<b>300 pg mL<sup>-1</sup></b>	2 ± 0.1	2.800 ± 0.001	0.971 ± 0.007	128 ± 1	0.132
<b>450 pg mL<sup>-1</sup></b>	2 ± 0.1	2.789 ± 0.005	0.959 ± 0.003	97 ± 0.5	0.100
<b>600 pg mL<sup>-1</sup></b>	2 ± 0.1	2.801 ± 0.007	0.959 ± 0.009	77 ± 0.3	0.159
<b>1000 pg mL<sup>-1</sup></b>	2 ± 0.1	2.799 ± 0.004	0.968 ± 0.001	35 ± 0.3	0.309

380

381 CPE1 and CPE2 values are not affected by the increase of the IL-8 concentration and remains

382 constant. However, the resistance of the charge transfer R<sub>ct1</sub> and R<sub>ct2</sub> were found to be the



383 most sensitive to the changes in IL-8 concentration and were, thus, selected as the relevant  
384 parameters to monitor the sensitivity of both developed immunosensors. The MWCNT based  
385 immunosensor is more sensitive promoting of the electron transfer thanks to carbon nanotubes  
386 properties and their particularity to amplify the response signal from antibody–antigen  
387 interaction and to improve the immunosensors characteristics. In fact, the MWCNTs facilitate  
388 the electron transfer between the electroactive species and the electrodes and facile oxidation  
389 and reduction kinetics [46]. Thus, , the calibration curves for both systems corresponding to  
390 the variation of the charge transfer resistance  $R_{ct}$  vs IL-8 concentrations were realised in order  
391 to quantify the biosensors response, and they could be find in Fig. 2S (Supplementary  
392 material section).

393 The immunosensors calibration curves present a linear relationship between the resistance of  
394 the charge transfer and the IL-8 concentration ranging from  $150 \text{ pg mL}^{-1}$  to  $600 \text{ pg mL}^{-1}$  ( $R^2$   
395 = 0.9961) with a detection limit of  $100 \text{ pg mL}^{-1}$  for the aminothiols based two-dimensional  
396 (2D) platform and from  $1 \text{ pg mL}^{-1}$  to  $1000 \text{ pg mL}^{-1}$  ( $R^2 = 0.9969$ ) with a lower limit of  
397 detection of  $0.1 \text{ pg mL}^{-1}$  for the MWCNTs based immunosensor, covering the entire  
398 clinically interesting range of IL-8 concentrations, which is very important not only for the  
399 early-stage diagnosis and screening procedures, but also in mapping the stage of the cancer  
400 too. Comparing both spatially hierarchical nano-architectures, we can notice that the use of  
401 MWCNT-COOH modified gold electrodes leads to a lower detection limit and a higher  
402 saturation limit with an extended linear range against IL-8 concentration [36]. This can be due  
403 to the higher concentration of immobilised anti IL-8 ( $22 \pm 1 \text{ } \mu\text{g mL}^{-1}$ ) due to the three-  
404 dimensional (3D) structure of MWCNTs based nano-architecture that offers a larger specific  
405 surface area. Moreover, the MWCNTs play a dual amplification role in both the recognition  
406 and transduction events. In addition, we can notice that the use of EIS provides a direct  
407 method of Antibody–Antigen binding and offers fast, sensitive, selective and quantitative  
408 responses [47–49]. Therefore, the impedimetric MWCNTs based three-dimensional  
409 immunosensor was selected for further evaluation of selectivity and possible application.  
410 The reproducibility of both impedimetric immunosensors was investigated by repeated  
411 experiments ( $n = 3$ ). A relative standard deviation of 7 % was obtained for the first system  
412 based on aminothiols and of 3 % for the MWCNTs based three-dimensional platform. The  
413 response of the developed impedimetric immunosensors was almost completely stable for one  
414 month.

415

### 416 **3.6 Selectivity**


417 Another important parameters related to the analytical performances of MWCNTs based  
418 three-dimensional immunosensor is its specificity and selectivity. Therefore, the ability of the  
419 biosensor to discriminate IL-8 from foreign species was investigated by evaluating the signal  
420 responses of the developed immunosensor to IL-8 against two other interfering compounds.  
421 This study was applied to Interleukin-1 (IL-1) and Interleukin-6 (IL-6). The selected non-  
422 specific antigen (IL-1 and IL-6) have been also demonstrated to be overexpressed in the  
423 presence of different cancers [50,51]. In general, the observed selectivity will depend mostly  
424 on the selectivity/specificity of the Ab/Ag reaction and of the non-specific response presented  
425 by the immunosensor platform. At the same concentration, the signal produced by the  
426 biosensor in the presence of the target analyte (IL-8) was always higher by at least 3 orders of  
427 magnitude compared to that observable by analyzing possible interferents (IL-1 and IL-6). A  
428 clear increase in signal was observed in presence of IL-8. In contrast, no significant signal  
429 was observed for IL-1 and IL-6 even at high concentration level of  $1000 \text{ pg mL}^{-1}$  and  
430 consequently, we did not observe significant influence during the detection of IL-8 when  
431 mixed IL-1 and IL-6. This result confirmed the higher affinity of IL-8 and brings out the  
432 specific and selective properties of the developed MWCNTs based immunosensor. The  
433 average  $R_{ct}$  changes produced by the addition of  $1 \text{ pg mL}^{-1}$  IL-8,  $1000 \text{ pg mL}^{-1}$  IL-1 and  $1000$   
434  $\text{pg mL}^{-1}$  IL-6 are presented in Fig. 3S (Supplementary materials section).

435

### 436 **3.7 Test in commercialised artificial plasma**

437 The goal of the present work was the development of a spatially hierarchical nano-  
438 architecture based electrochemical immunosensor for real time detection, in human samples,  
439 of IL-8, that can be considered as early warning marker for cancer disease. Thus, the  
440 suitability of the developed MWCNT based immunosensor for the detection of IL-8 in real  
441 sample was investigated by testing the impedimetric signal response in artificial plasma. So,  
442 in order to reduce the non-specific adsorption, the artificial plasma was diluted 1000 times  
443 and has been used to prepare the solutions of IL-8 with increasing concentrations ranging  
444 from  $1 \text{ pg mL}^{-1}$  to  $1000 \text{ pg mL}^{-1}$ . Fig. 6 illustrates the response of the MWCNTs based  
445 immunosensor towards increasing concentrations of IL-8 in the artificial commercialised  
446 plasma diluted 1000 times.

447



448  
 449 **Fig. 6.** MWCNTs based immunosensor response towards increasing concentrations of IL-8 in the  
 450 artificial commercialised plasma diluted 1000 times.

451  
 452 We can observe a considerable dependence of the normalised signal of the developed  
 453 immunosensor as a function of the IL-8 concentration. Then, in order to prove the absence of  
 454 non-specific adsorption when detecting IL-8 antigen, we have investigated the response of the  
 455 sensor towards IL-1 and IL-6 as blank tests. The impedimetric response of aminothioli/  
 456 activated MWCNT/ anti IL-8 based immunosensor towards the interfering compounds  
 457 presented a shift between the two first half-circles. This could be due to the adsorption of  
 458 proteins found in commercialised artificial plasma. Then, the response of the MWCNTs based  
 459 nano-architecture was almost the same regardless the increasing concentrations of IL-1 and  
 460 IL-6. This brings out the high sensitivity and specificity of the developed three-dimensional  
 461 based impedimetric immunosensor towards IL-8 antigen in artificial plasma, which suggests  
 462 the possibility of using it in routine procedures for real time monitoring, diagnostic and  
 463 prognostic of tumor development and progression.  
 464 To highlight the advantage of our promising results, Table 4 reports linear concentration  
 465 ranges and LoDs obtained from other biosensors developed for IL-8 quantification in blood  
 466 (plasma and serum) by binding with an antibody immobilized onto the working electrode.  
 467 Compared to them, our device stated lower LoD and wider linear range in addition to a rapid  
 468 time-analysis and higher selectivity. Moreover, our biosensor resulted more competitive even  
 469 if compared to the gold standard assays (ELISAs) for IL-8 quantification in blood (plasma  
 470 and serum), since these assays require longer analysis times (from 4 up to 7 hours), trained  
 471 personnel and sophisticated equipment, and most of these commercially available IL-8 ELISA  
 472 kits have proven LoDs of about  $15 \pm 5 \text{ pg mL}^{-1}$ , thus higher than our and above the IL-8 basal  
 473 clinical level of  $5 - 10 \text{ pg mL}^{-1}$  commonly detected in healthy patients [25].

474  
475  
476  
477  
478  
479  
480

**Table 2.** Comparison of different antibody-based electrochemical immunosensors for IL-8 detection in blood (plasma and serum). Abbreviations: Au: gold; LOD: limit of detection; Ab: antibody; cys: cysteine; C<sub>60</sub>: spherical fullerenes; ASV: anodic stripping voltammetry; LSV: linear sweep voltammetry; Ti: titanium; TNT: titanium dioxide nanotube.

Transducer	Sensing (Technique)	Linear range	LOD (matrix)	Reference
Carbon electrode	C <sub>60</sub> / Ab (ASV/ LSV)	1.25 – 5 ng mL <sup>-1</sup>	0.61 ± 0.05 ng mL <sup>-1</sup> (buffer)	[26]
	MWCNTs/Ab (ASV/ LSV)	5 – 20 ng mL <sup>-1</sup>	0.39 ± 0.10 ng mL <sup>-1</sup> (buffer)	
Ti electrode	Ti/TNT/Ab (EIS)	5 – 2500 pg mL <sup>-1</sup>	5 pg mL <sup>-1</sup> (PBS)	[52]
Au electrode	Aminothiols/Ab (EIS)	150 – 600 pg mL <sup>-1</sup>	100 pg mL <sup>-1</sup> (artificial human plasma)	This work
	Aminothiols/MWCNTs/Ab (EIS)	1 – 1000 pg mL <sup>-1</sup>	0.1 pg mL <sup>-1</sup> (artificial human plasma)	

481  
482  
483

#### 4. Conclusions

484 In this study, two different spatially hierarchical nano-architectures for real time detection of  
485 Interleukin-8 cancer biomarker were developed. A two-dimensional based platform was  
486 established by immobilising the activated anti IL-8 onto the aminothiols modified working  
487 gold electrode. Then, the integration of MWCNTs, in the functionalisation process, allowed to  
488 create a three-dimensional nano-architecture. The electronic properties of MWCNTs and  
489 specially their band structure, in terms of density of electronic states, were very important for  
490 the interfacial electron transfer between the electroactive species in solution and the working  
491 electrode surface. Thus, the use of MWCNTs based three-dimensional nano-architecture leads  
492 to the development of a successful and reproducible IL-8 cancer biomarker sensor by  
493 improving the immunosensor performances with a low limit of detection and a large linear  
494 sensitive range covering the entire clinically interesting range of IL-8 concentrations which is  
495 very important not only for the early-stage diagnosis and screening procedures, but also in  
496 mapping the stage of the cancer too. Moreover, this device would also represent a promising  
497 starting point for further future applications, including its use for saliva analysis, opening the  
498 possibility of non-invasive and non-stressful approach to cancer management.

499

500 **CRedit author statement**

501 Sawsen Azzouzi: Experimental research, Investigation, Writing- Original draft  
502 preparation. Mounir Ben Ali: Conceptualization, Methodology, Formal analysis, Supervision,  
503 Project administration. Francesca G. Bellagambi: Formal analysis, Reviewing and Editing.  
504 Abdelhamid Elaissari: Validation, Editing, Project administration. Nicole Jaffrezic-Renault:  
505 Conceptualization, Methodology, Validation, Editing. Abdelhamid Errachid:  
506 Conceptualization, Methodology, Supervision, Funding acquisition, Project administration.  
507 Nadia Zine: Conceptualization, Methodology, Supervision, Funding acquisition, Project  
508 administration.

509

### 510 **Declaration of competing interest**

511 The authors declare that they have no known competing financial interests or personal  
512 relationships that could have appeared to influence the work reported in this paper.

513

### 514 **Acknowledgements**

515 This work was partially supported by the H2020 projects KardiaTool (Grant No. 768686)  
516 and WIDESPREAD project (Grant No. 951887), and by POC4Allergies project funded within  
517 the ERA PerMed – 2<sup>nd</sup> Joint Transnational Call for proposals.

518

### 519 **References**

- 520 [1] P. Kuppusamy, N. Govindan, M.M. Yusoff, S.J.A. Ichwan, Proteins are potent  
521 biomarkers to detect colon cancer progression, *Saudi J. Biol. Sci.* 24 (2017):1212–1221.  
522 <https://doi.org/10.1016/j.sjbs.2014.09.017>.
- 523 [2] R. Gasparri, G. Sedda, L. Spaggiari, Biomarkers in early diagnosis and early stage lung  
524 cancer: The clinician's point of view, *J. Clin. Med.* 9 (2020) 1790.  
525 <https://doi.org/doi:10.3390/jcm9061790>.
- 526 [3] U. Landegren, M. Hammond, Cancer diagnostics based on plasma protein biomarkers:  
527 hard times but great expectations, *Mol. Oncol.* 15 (2021) 1715–1726.  
528 <https://doi.org/10.1002/1878-0261.12809>.
- 529 [4] N.C. Japp, J.J. Soucek, A.R. Sasson, M.A. Hollingsworth, S.K. Batra, W.M. Junker,  
530 Tumor biomarker in-solution quantification, standard production, and multiplex  
531 detection, *J. Immunol. Res.* 2021 (2021) 9942605. <https://doi.org/10.1155/2021/9942605>.

- 532 [5] E. Dama, T. Colangelo, E. Fina, M. Cremonesi, M. Kallikourdis, G. Veronesi, F.  
533 Bianchi, Biomarkers and lung cancer early detection: State of the art, *Cancers*. 13 (2021)  
534 3919. <https://doi.org/10.3390/cancers13153919>.
- 535 [6] S. Aitekenov, A. Gaipov, R. Bukasov, Review: Detection and quantification of proteins  
536 in human urine, *Talanta*. 223 (2021) 121718.  
537 <https://doi.org/10.1016/j.talanta.2020.121718>.
- 538 [7] R. Bhawal, A.L. Oberg, S. Zhang, M. Kohli, Challenges and opportunities in clinical  
539 applications of blood-based proteomics in cancer, *Cancers (Basel)*. 12 (2020) 2428.  
540 <https://doi.org/10.3390/cancers12092428>.
- 541 [8] D. Vozgirdaite, H. Ben Halima, F.G. Bellagambi, A. Alcacer, F. Palacio, N. Jaffrezic-  
542 Renault, N. Zine, J. Bausells, A. Elaissari, A. Errachid, Development of an ImmunoFET  
543 for analysis of tumour necrosis factor- $\alpha$  in artificial saliva: Application for heart failure  
544 monitoring, *Chemosensors*. 9 (2021) 26. <https://doi.org/10.3390/chemosensors9020026>.
- 545 [9] H. Ben Halima, F.G. Bellagambi, A. Alcacer, N. Pfeiffer, A. Heuberger, A. Hangouët,  
546 N. Zine, J. Bausells, A. Elaissari, A. Errachid, A silicon nitride ISFET based  
547 immunosensor for tumor necrosis factor-alpha detection in saliva. A promising tool for  
548 heart failure monitoring, *Anal. Chim. Acta* 1161 (2021) 338468.  
549 <https://doi.org/10.1016/j.aca.2021.338468>.
- 550 [10] J.A. Stenken, A.J. Poschenrieder, Bioanalytical chemistry of cytokines--a review, *Anal.*  
551 *Chim. Acta*. 853 (2015) 95–115. <https://doi.org/10.1016/j.aca.2014.10.009>.
- 552 [11] A.S. Gokhale, R.I. Haddad, L.A. Cavacini, L. Wirth, L. Weeks, M. Hallar, J. Faucher,  
553 M.R. Posner, Serum concentrations of interleukin-8, vascular endothelial growth factor,  
554 and epidermal growth factor receptor in patients with squamous cell cancer of the head  
555 and neck, *Oral Oncol*. 41 (2005) 70–76.  
556 <https://doi.org/10.1016/j.oraloncology.2004.06.005>.
- 557 [12] T.P. Kobawala, G.H. Patel, D.R. Gajjar, K.N. Patel, P.B. Thakor, U.B. Parekh, K.M.  
558 Patel, S.N. Shukla, P.M. Shah, Clinical utility of serum interleukin-8 and interferon-alpha  
559 in thyroid diseases, *J. Thyroid Res*. 2011 (2011) 270149.  
560 <https://doi.org/10.4061/2011/270149>.
- 561 [13] M. Gonzalez-Aparicio, C. Alfaro, Significance of the IL-8 pathway for immunotherapy,  
562 *Hum. Vaccin. Immunother*. 16 (2020) 2312–2317.  
563 <https://doi.org/10.1080/21645515.2019>.
- 564 [14] R. Aalinkeel, M. P.R. Nair, G. Sufrin, S. D. Mahajan, K. C. Chadha, R. P. Chawda, S. A.  
565 Schwartz, *Cancer Reaserach* 64 (2009) 5311–5321.

- 566 [15] V. Merz, C. Zecchetto, R. Santoro, F. Simionato, F. Sabbadini, D. Mangiameli, G. Piro,  
567 A. Cavaliere, M. Deiana, M.T. Valenti, D. Bazan, V. Fedele, S. Lonardi, D. Melisi,  
568 Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to  
569 Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer,  
570 Clin Cancer Res 26 (2020) 4661–4669. <https://doi.org/10.1158/1078-0432.CCR-20-0395>.
- 571 [16] C. Alfaro, M.F. Sanmamed, M.E. Rodríguez-Ruiz, Á. Teijeira, C. Oñate, Á. González,  
572 M. Ponz, K.A. Schalper, J.L. Pérez-Gracia, I. Melero, Interleukin-8 in cancer  
573 pathogenesis, treatment and follow-up, Cancer Treat. Rev. 60 (2017) 24–31.  
574 <https://doi.org/10.1016/j.ctrv.2017.08.004>.
- 575 [17] Z. Bakouny, T.K. Choueiri, IL-8 and cancer prognosis on immunotherapy, Nat. Med. 26  
576 (2020) 650–651. <https://doi.org/10.1038/s41591-020-0873-9>.
- 577 [18] B.A. Otieno, C.E. Krause, A. Latus, B.V. Chikkaveeraiah, R.C. Faria, J.F. Rusling, On-  
578 line Protein Capture on Magnetic Beads for Ultrasensitive Microfluidic Immunoassays of  
579 Cancer Biomarkers, Biosens. Bioelectron. 53 (2014) 268–274.  
580 <https://doi.org/10.1016/j.bios.2013.09.054>.
- 581 [19] P. Domnanich, D.B. Pena, C. Preininger, Xanthan/chitosan gold chip for metal enhanced  
582 protein biomarker detection, Biosens. Bioelectron. 26 (2011) 2559–2565.  
583 <https://doi.org/10.1016/j.bios.2010.11.006>.
- 584 [20] P.S. Waggoner, C.P. Tanb, H.G. Craighead, Microfluidic integration of nanomechanical  
585 resonators for protein analysis in serum, Sens. Actuators B-Chem. 150 (2010) 550–555.  
586 <https://doi.org/10.1016/j.snb.2010.08.041>.
- 587 [21] R. Malhotra, V. Patel, B.V. Chikkaveeraiah, B.S. Munge, S.C. Cheong, R.B. Zain, M.T.  
588 Abraham, D.K. Dey, J.S. Gutkind, J. F. Rusling, Ultrasensitive detection of cancer  
589 biomarkers in the clinic by use of a nanostructured microfluidic array, Anal. Chem. 84  
590 (2012) 6249–6255. <https://doi.org/10.1021/ac301392g>.
- 591 [22] S. Mandal, J.M. Goddard, D. Erickson, A multiplexed optofluidic biomolecular sensor  
592 for low mass detection, Lab. Chip. 9 (2009) 2924–2932.  
593 <https://doi.org/10.1039/b907826f>.
- 594 [23] M.M.A. Hakim, M. Lombardini, K. Sun, F. Giustiniano, P.L. Roach, D.E. Davies, P.H.  
595 Howarth, M.R.R. Planque, H. Morgan, P. Ashburn, Thin film polycrystalline silicon  
596 nanowire biosensors, Nano Lett. 12 (2012) 1868–1872.  
597 <https://doi.org/10.1021/nl2042276>.
- 598 [24] J.T. Kindt, M.S. Luchansky, J. Abraham, A.J. Qavi, S.H. Lee, R.C. Bailey, Subpicogram  
599 per milliliter detection of interleukins using silicon photonic microring resonators and an

600 enzymatic signal enhancement strategy, *Anal. Chem.* 85 (2013) 10653–10657.  
601 <https://doi.org/10.1021/ac402972d>.

602 [25] R. Sharma, S.E. Deacon, D. Nowak, S.E. George, M.P. Szymonik, A. Tang, D.C.  
603 Tomlinson, A.G. Davies, M.J. McPherson, C. Wälti, C. (2016). Label-free  
604 electrochemical impedance biosensor to detect human interleukin-8 in serum with sub-  
605 pg/ml sensitivity. *Biosensors & bioelectronics*, 80 (2016) 607–613.  
606 <https://doi.org/10.1016/j.bios.2016.02.028>.

607 [26] S. Tonello, M. Marziano, G. Abate, T. Kilic, M. Memo, D. Uberti, S. Carrara, N.F.  
608 Lopomo, M. Serpelloni, E. Sardini, Enhanced sensing of interleukin 8 by stripping  
609 voltammetry: Carbon nanotubes versus fullerene, in: Eskola H., Väisänen O., Viik J.,  
610 Hyttinen J. (eds) EMBEC & NBC 2017. EMBEC 2017, NBC 2017. IFMBE Proceedings,  
611 vol 65. Springer, Singapore, 2018, pp. 213–216. [https://doi.org/10.1007/978-981-10-](https://doi.org/10.1007/978-981-10-5122-7_54)  
612 [5122-7\\_54](https://doi.org/10.1007/978-981-10-5122-7_54).

613 [27] J. Verbarq, O. Hadass, P.D. Olivo, A. Danielli, High sensitivity detection of a protein  
614 biomarker interleukin-8 utilizing a magnetic modulation biosensing system, *Sens.*  
615 *Actuators B-Chem.* 241 (2017) 614–618. <https://doi.org/10.1016/j.snb.2016.10.089>.

616 [28] J. Bausells, H. Ben Halima, F.G. Bellagambi, A. Alcacer, N. Pfeiffer, M. Hangouët, N.  
617 Zine, A. Errachid, On the impedance spectroscopy of field-effect biosensors,  
618 *Electrochem. Sci. Adv.* 2021 (2021) e2100138. [https://doi.org/](https://doi.org/doi.org/10.1002/elsa.202100138)  
619 [doi.org/10.1002/elsa.202100138](https://doi.org/10.1002/elsa.202100138).

620 [29] B. V. Chikkaveeraiah, A. A. Bhirde, N. Y. Morgan, H. S. Eden, X. Chen,  
621 *Electrochemical Immunosensors for Detection of Cancer Protein Biomarkers*, *ACS Nano*  
622 6 (2012) 6546–6561. <https://doi.org/10.1021/nn3023969>.

623 [30] C. Paoletti, M. He, P. Salvo, B. Melai, N. Calisi, M. Mannini, B. Cortigiani, F.G.  
624 Bellagambi, T.M. Swager, F. Di Francesco, A. Pucci, Room temperature amine sensors  
625 enabled by sidewall functionalization of single-walled carbon nanotubes, *RSC Adv.* 8  
626 (2018) 5578–5585. <https://doi.org/10.1039/C7RA13304A>.

627 [31] M. Nurazzi Norizan, M.H. Moklis, S.Z. Ngah Demon, N.A. Halim, A. Samsuri, I.S.  
628 Mohamad, V.F. Knight, N. Abdullah, Carbon nanotubes: functionalisation and their  
629 application in chemical sensors, *RSC Adv.* 10 (2020) 43704–43732.  
630 <https://doi.org/10.1039/D0RA09438B>.

631 [32] N.G. Welch, J.A. Scoble, B.W. Muir, P.J. Pigram, Orientation and characterization of  
632 immobilized antibodies for improved immunoassays (Review), *Biointerphases.* 12 (2017)  
633 02D301. <https://doi.org/10.1116/1.4978435>.



- 634 [33] S. Chen, L. Liu, J. Zhou, S. Jiang, Controlling Antibody Orientation on Charged Self-  
635 Assembled Monolayers, *Langmuir*. 19 (2003) 2859–2864.  
636 <https://doi.org/10.1021/la026498v>.
- 637 [34] A. Baraket, M. Lee, N. Zine, N. Yaakoubi, M.G. Trivella, A. Elaissari, M. Sigaud, N.  
638 Jaffrezic-Renault, A. Errachid, A flexible label-free biosensor sensitive and selective to  
639 TNF- $\alpha$ : application for chronic heart failure, *Sens. Transducers*. 27 (2014), 15–21.
- 640 [35] E. Venturelli, C. Fabbro, O. Chaloin, C. Ménard-Moyon, C.R. Smulski, T. Da Ros, K.  
641 Kostarelos, M. Prato, A. Bianco, Antibody covalent immobilization on carbon nanotubes  
642 and assessment of antigen binding, *Small*. 7 (2011) 2179–2187.  
643 <https://doi.org/10.1002/smll.201100137>.
- 644 [36] M. Ben Ali, F. Bessueille, J.M. Chovelon, A. Abdelghani, N. Jaffrezic-Renault, M.A.  
645 Maaref, C. Martelet, Use of ultra-thin organic silane films for the improvement of gold  
646 adhesion to the silicon dioxide wafers for (bio)sensor applications, *Mater. Sci. Eng. C* 28  
647 (2008) 628–632. <https://doi.org/10.1016/j.msec.2007.10.048>.
- 648 [37] N.S. Ferreira, M.G.F. Sales, Disposable immunosensor using a simple method for  
649 oriented antibody immobilization for label-free real-time detection of an oxidative stress  
650 biomarker implicated in cancer diseases, *Biosens. Bioelectron*. 53 (2014) 193–199.  
651 <https://doi.org/10.1016/j.bios.2013.09.056>.
- 652 [38] S. Bourigua, A. Maaref, A. Errachid, F. Bessueille, N. Jaffrezic-Renault, Immunosensors  
653 based on single-walled carbon nanotubes (SWCNT) for the detection of deep venous  
654 thrombosis, *Sens. Transducers*. 27 (2014) 127–136.
- 655 [39] S. Bourigua, M. Hnaïen, F. Bessueille, F. Lagarde, S. Dzyadevych, A. Maaref, J.  
656 Bausells, A. Errachid, N. Jaffrezic Renault, Impedimetric immunosensor based on  
657 SWCNT-COOH modified gold microelectrodes for label-free detection of deep venous  
658 thrombosis biomarker, *Biosens Bioelectron*. 26 (2010) 1278–1282.  
659 <https://doi.org/10.1016/j.bios.2010.07.004>.
- 660 [40] F.G. Bellagambi, A. Baraket, A. Longo, M. Vatteroni, N. Zine, J. Bausells, R. Fuoco, F.  
661 Di Francesco, G.S. Karanasiou, D.I. Fotiadis, A. Menciassi, A. Errachid, Electrochemical  
662 biosensor platform for TNF- $\alpha$  cytokines detection in both artificial and real human saliva:  
663 Heart failure, *Sens. Actuators B Chem*. 251 (2017) 1026–1033.  
664 <https://doi.org/10.1016/j.snb.2017.05.169>.
- 665 [41] L. Barhoumi, A. Baraket, F.G. Bellagambi, G.S. Karanasiou, M. Ben Ali, D.I. Fotiadis, J.  
666 Bausells, N. Zine, M. Sigaud, A. Errachid, A novel chronoamperometric immunosensor

667 for recombinant human TNF- $\alpha$  detection. *Sens. Actuators B Chem.* 266 (2018) 477–484.  
668 <https://doi.org/10.1016/j.snb.2018.03.135>.

669 [42] L. Barhoumi, F.G. Bellagambi, F.M. Vivaldi, A. Baraket, Y. Clément, N. Zine, M. Ben  
670 Ali, A. Elaissari, A. Errachid, Ultrasensitive immunosensor array for TNF- $\alpha$  detection in  
671 artificial saliva using polymer-coated magnetic microparticles onto screen-printed gold  
672 electrode, *Sensors. (Basel.)* 19 (2019) 692. <https://doi.org/10.3390/s19030692>.

673 [43] M. Hnaïen, S. Bourigu, F. Bessueille, J. Bausells, A. Errachid, F. Lagard, N. Jaffrezic-  
674 Renault, Impedimetric microbial biosensor based on single wall carbon nanotube  
675 modified microelectrodes for trichloroethylene detection, *Electrochim. Acta* 56 (2011)  
676 10353–10358. <https://doi.org/10.1016/j.electacta.2011.04.041>.

677 [44] M. Ben Ali, Y. Korpan, M.A. Gonchar, El'skaya, M.A. Maaref, , N. Jaffrezic-Renault, C.  
678 Martelet, Formaldehyde assay by capacitance versus voltage and impedance  
679 measurements using bi-layer bio-recognition membrane, *Biosens. Bioelectron.* 22 (2006)  
680 575–581. <https://doi.org/10.1016/j.bios.2006.01.019>.

681 [45] M. Barreiros dos Santos, J.P. Aguil, B. Prieto-Simon, C. Sporer, V. Teixeira, J.  
682 Samitier, Highly sensitive detection of pathogen *Escherichia coli* O157:H7 by  
683 electrochemical impedance spectroscopy, *Biosens. Bioelectron.* 45 (2013) 174–180.  
684 <https://doi.org/10.1016/j.bios.2013.01.009>.

685 [46] N. J. Ronkainen, H.B. Halsall, W.R. Heineman, Electrochemical biosensors, *Chem. Soc.*  
686 *Rev.* 39 (2010) 1747–1763. <https://doi.org/10.1039/b714449k>.

687 [47] L.G. Zamfir, I. Geana,1, S. Bourigua, L. Rotariu, C. Bala, A. Errachid, N. Jaffrezic-  
688 Renault, Highly sensitive label-free immunosensor for ochratoxin A based on  
689 functionalized magnetic nanoparticles and EIS/SPR detection, *Sens. Actuators B Chem.*  
690 159 (2011) 178– 184. <https://doi.org/10.1016/j.snb.2011.06.069>.

691 [48] M. Lee, N. Zine, A. Baraket, M. Zabala, F. Campabadal, R. Caruso, M.G. Trivella, N.  
692 Jaffrezic-Renault, A. Errachid, A novel biosensor based on hafnium oxide: Application  
693 for early stage detection of human interleukin-10, *Sens. Actuators B Chem.* 175 (2012)  
694 201– 207. <https://doi.org/10.1016/j.snb.2012.04.090>.

695 [49] A. Baraket, M. Lee, N. Zine, M. Sigaud, N. Yaakoubi, M. G. Trivella, M. Zabala, J.  
696 Bausells, N. Jaffrezic-Renault, A. Errachid, Diazonium modified gold microelectrodes  
697 onto polyimide substrates for impedimetric cytokine detection with an integrated  
698 Ag/AgCl reference electrode, *Sens. Actuators B Chem.* 189 (2013) 165–172.  
699 <https://doi.org/10.1016/j.snb.2013.02.088>.

700 [50] V. Gelfo, D. Romaniello, M. Mazzeschi, M. Sgarzi, G. Grilli, A. Morselli, B. Manzan, K.  
701 Rihawi, M. Lauriola, Roles of IL-1 in cancer: From tumor progression to resistance to  
702 targeted therapies, *Int. J. Mol. Sci.* 21 (2020) 6009.  
703 <https://doi.org/10.3390/ijms21176009>.

704 [51] T. Hirano, IL-6 in inflammation, autoimmunity and cancer, *Int. Immunol.* 33 (2021)  
705 127–148. <https://doi.org/10.1093/intimm/dxaa078>.

706 [52] K. Arkusz, E. Paradowska, Impedimetric Detection of femtomolar levels of Interleukin6,  
707 Interleukin 8, and Tumor Necrosis Factor Alpha based on thermally modified  
708 nanotubular titanium dioxide arrays, *Nanomaterials (Basel)*. 10 (2020) 2399.  
709 <https://doi.org/10.3390/nano10122399>.

710  
711  
712